Phio Pharmaceuticals Corp.
Datakwaliteit: 83%
PHIO
Nasdaq
Manufacturing
Chemicals
€ 1,26
▼
€ 0,05
(-3,46%)
Marktkapitalisatie: 14,58 M
Prijs
€ 1,26
Marktkapitalisatie
14,58 M
Dagbereik
€ 1,25 — € 1,28
52-Weeksbereik
€ 0,81 — € 4,19
Volume
53.133
Openen € 1,25
50D / 200D Gem.
€ 1,15
9,15% above
50D / 200D Gem.
€ 1,70
26,05% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -7,99 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-87,27%
Onder sectorgemiddelde (-51,02%)
ROIC-71,43%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A
Waardering
PE (TTM)
-1,68
Boven sectorgemiddelde (-1,98)
P/B Ratio1,48
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (44 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (44 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -1,7 | -2,0 |
| P/B | 1,5 | 5,1 |
| ROE % | -87,3 | -51,0 |
| Net Margin % | — | -150,2 |
| Rev Growth 5Y % | — | 9,3 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -8,70 M |
| ROE | -87,27% | ROA | -76,28% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -7,99 M |
| ROIC | -71,43% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | N/A |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | N/A | Tangible Book Value | 9,84 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1,68 | Forward P/E | N/A |
| P/B Ratio | 1,48 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -54,81% | ||
| Market Cap | 14,58 M | Enterprise Value | 3,87 M |
| Per Share | |||
| EPS (Diluted TTM) | N/A | Revenue / Share | N/A |
| FCF / Share | -0,69 | OCF / Share | -0,69 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 91,87% |
| SBC-Adj. FCF | -8,25 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -8,70 M | -7,15 M | -10,83 M | -11,48 M | -13,29 M |
| EPS (Diluted) | — | -9,08 | -5,20 | -10,10 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -9,22 M | -7,39 M | -10,82 M | -11,46 M | -13,51 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 4,62 M | 3,64 M | 6,33 M | 7,01 M | 8,89 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 3.000,0 | 2.000,0 | 56.000,0 | 71.000,0 | 75.000,0 |
| Interest Expense | — | 231.000,0 | — | — | — |
| Income Tax | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 21,49 M | 5,74 M | 9,36 M | 12,81 M | 25,17 M |
| Total Liabilities | 1,34 M | 1,02 M | 1,63 M | 1,97 M | 3,24 M |
| Shareholders' Equity | 20,15 M | 4,72 M | 7,73 M | 10,84 M | 21,93 M |
| Total Debt | — | — | — | — | 0,0 |
| Cash & Equivalents | 21,03 M | 5,38 M | — | — | — |
| Current Assets | 21,48 M | 5,74 M | 9,32 M | 12,45 M | 24,73 M |
| Current Liabilities | — | 1,02 M | 1,63 M | 1,94 M | 3,07 M |
{"event":"ticker_viewed","properties":{"ticker":"PHIO","listing_kind":"stock","pathname":"/stocks/phio","exchange":"Nasdaq","country":"US"}}